Pepric appoints Dr. Enrico Bastianelli as independent Director

Pepric appoints Dr. Enrico Bastianelli as independent Director.

The General Assembly of Pepric appointed Dr. Enrico Bastianelli as independent non-executive Board member. Dr. Bastianelli is the CEO of Bone Therapeutics since 2006, a cell therapy company for bone fracture repair and prevention. Previously, Dr. Bastianelli gained a tremendous expertise in the cell and pharmaceutical industry based on many years of experience at Procter and Gamble Pharmaceuticals, McKinsey & Co and ProSkelia.

“We are delighted to welcome Dr. Bastianelli to the Board of Pepric, developing instrumentation for cell and particle detection and imaging.  His experience and profound understanding of the end-users market of Pepric’s technology will deliver substantial benefit in the decision making process.”, said Stephanie Teughels, CEO of Pepric            

Commenting on his appointment, Dr. Bastianelli said: “I’m pleased to join Pepric offering new solutions for targeted molecular imaging and longitudinal cell detection. I’m looking forward to contribute to its business strategy to maximize the potential of its innovative instruments.”

Contact:

Pepric nv, Stephanie Teughels CEO, Kapeldreef 75, B-3001 Leuven, http://www.pepric.com/
Tel +32 16 28 82 82, stephanie.teughels@pepric.com

About Pepric

Pepric develops and commercializes instrumentation for quantitative cell and molecular detection and imaging. The tools find applications in the longitudinal and quantitative monitoring of the distribution and kinetics of cells and particles. Pepric was founded in 2009 as a spin-off company of Imec, and has its headquarters in Leuven, Belgium.